Medtronic Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss decreased by 2.1% to $47.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 62.4%, from $125.00M to $47.00M. Over 4 years (FY 2021 to FY 2025), Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss shows an upward trend with a 29.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase indicates that a significant portion of the portfolio is suffering from prolonged valuation declines, raising concerns about potential future write-downs.
The cumulative amount of unrealized losses for debt securities that have been in a continuous loss position for 12 month...
Standard disclosure for insurance companies to track the aging of unrealized losses.
other_debt_securities_available_for_sale_continuous_unre_23ad4c| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $32.00M | $29.00M | $49.00M | $79.00M | $244.00M | $267.00M | $456.00M | $331.00M | $297.00M | $317.00M | $337.00M | $219.00M | $238.00M | $162.00M | $128.00M | $125.00M | $91.00M | $75.00M | $48.00M | $47.00M |
| QoQ Change | — | -9.4% | +69.0% | +61.2% | +208.9% | +9.4% | +70.8% | -27.4% | -10.3% | +6.7% | +6.3% | -35.0% | +8.7% | -31.9% | -21.0% | -2.3% | -27.2% | -17.6% | -36.0% | -2.1% |
| YoY Change | — | — | — | — | +662.5% | +820.7% | +830.6% | +319.0% | +21.7% | +18.7% | -26.1% | -33.8% | -19.9% | -48.9% | -62.0% | -42.9% | -61.8% | -53.7% | -62.5% | -62.4% |